Welcome to our dedicated page for Palisade Bio news (Ticker: PALI), a resource for investors and traders seeking the latest updates and insights on Palisade Bio stock.
Palisade Bio, Inc. develops next-generation oral PDE4 inhibitor prodrugs for inflammatory and fibrotic diseases. Its lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed for targeted delivery and selective bioactivation in the ileum and colon, with clinical development focused on ulcerative colitis and Crohn’s disease.
Company news commonly covers PALI-2108 clinical and translational data, pharmacokinetic and biomarker findings, disease-conference presentations, clinical advisory activity and healthcare investor events. Updates also describe the company’s precision pharmacology strategy and the role of gut-targeted PDE4 inhibition in inflammatory bowel disease programs.
Palisade Bio, Inc. (Nasdaq: PALI) has received Fast Track Designation from the U.S. FDA for its investigational drug LB1148, aimed at reducing surgical adhesions after abdominal surgeries. This follows a prior designation for treating GI dysfunction in pediatric cardiovascular surgery patients.
LB1148 is designed to inhibit digestive proteases released during surgery, potentially addressing serious complications such as small bowel obstruction and chronic pain, which affect over 90% of post-abdominal surgery patients.
Palisade Bio has completed a Phase 2 clinical trial for its lead drug candidate LB1148, aimed at accelerating bowel function recovery post gastrointestinal (GI) surgery. The PROFILE study enrolled over 120 patients in China, focusing on the time to return of bowel function as a primary endpoint. Positive outcomes could significantly advance LB1148’s path towards approval. Early Phase 1 results indicated a 1.3-day reduction in hospital stay. The drug aims to address the critical need for new treatments in post-surgery bowel function.
Palisade Bio, Inc. (PALI) announced a key opinion leader (KOL) webinar on May 13, 2021, focusing on LB1148, its lead asset for gastrointestinal surgery complications. Featuring renowned KOLs, the webinar will cover postoperative bowel function recovery and adhesion reduction. LB1148, a serine protease inhibitor, has shown efficacy in a Phase 2 trial, improving bowel function recovery in cardiac surgery patients. A second Phase 2 trial is ongoing in GI surgery, with plans for a Phase 2/3 trial for pediatric surgeries. Positive Phase 2 data is expected by year-end 2021.
Leading BioSciences successfully completed its merger with Seneca Biopharma, establishing Palisade Bio, Inc., which will begin trading on Nasdaq under the ticker PALI on April 28, 2021. The merger is accompanied by a $20 million private placement led by Altium Capital, enhancing financial resources for trial advancements. Palisade Bio's lead asset, LB1148, shows promise in improving post-operative gastrointestinal function and has received Fast Track Designation from the FDA for pediatric applications. This positions Palisade for significant clinical milestones within the next 12 to 18 months.